Baxter International Inc. (NYSE:BAX) surged 3.93%
to $51.33. The company said Thursday
that third-quarter earnings were $595 million, of $1.01 a share compared to
$530 million, or 88 cents a share, in the year-ago period.
Analysts
polled by FactSet research estimated, on average, earnings per share of 98
cents and sales of $3.16 billion. The company sees fourth-quarter sales growth
of 1% to 2% and earnings per share of $1.09 to $1.11.
The
stock went down more than 13% year-to-date.
CARDIOME PHARMA CORP (NASDAQ:CRME) plunged 12.56%
to $5.57. The company announced a key Phase III clinical trial for its cardiac
drug vernakalant hydrochloride has been halted due to safety concerns.
The
company said that while an independent safety board has recommended the trial
continue, the study will remain halted pending a review by U.S. Food and Drug
Administration.
The
stock opened at $5.10 and is trading within the range of $5.10-$6.58.
Eli Lilly & Co. (NYSE:LLY) dropped 0.92%
to $35.68. The company said it earned $1.3 billion, or $1.18 a share, compared
with $942 million, or 86 cents a share, for the 2009 quarter.
A poll
of analysts by FactSet pegged Lilly at earning $1.15 a share, on revenue of
$5.79 billion.
Over the
past 52-week, the stock traded within the range of $32.02-$38.08. The stock went
down more than 1% year-to-date.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) jumped 2.19%
to $69.56. The company said that in Phase II trials, Soliris, a treatment for
hemolytic uremic syndrome, met its primary and key secondary endpoints.
The
company posted a higher-than-expected rise in quarterly profit, and signalled
that its genetic disorder drug was moving closer to approval in a new
indication.
Third-quarter
net income was $27.9 million, or 30 cents a share, compared to $26.7 million,
or 29 cents a share in the year-ago period.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today. For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
